TWiV 941: Clinical update with Dr. Daniel Griffin
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In his weekly clinical update Dr. Griffin discusses increased acute respiratory illnesses among children and adolescents, estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant, breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination, interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses, further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants, short-course early outpatient Remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA.2 wave, effectiveness of Molnupiravir in high risk patients, and primary care and a distinct symptom pattern for long COVID.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Research assistant position with Amy Rosenfeld (pdf)
- Support MicrobeTV with a Spike t-shirt at Vaccinated.US
- Increase in Acute Respiratory illnesses among children and adolescents (CDC)
- Estimates of Monkeypox incubation period, generation time, reproduction number (CDC)
- Rapid increase in suspected SARS-CoV-2 reinfections (CDC)
- Infection prevention and control recommendations for healthcare providers (CDC)
- SARS-CoV-2 attack rate in vaccinated and unvaccinated household contacts (CDC)
- Breakthrough Infection by variants elicited immune response comparable to vaccine (JID)
- Interval between prior SARS-CoV-2 infection and booster vaccination impacts (CELL)
- Humoral immunity evasion of BA.4 and BA.5 subvariants (The Lancet)
- Outpatient Remdesivir prevents severe disease in organ transplant recipients (Am J Transplant)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Effectiveness of Molnupiravir in high risk patients (CID)
- Update on Long COVID for primary care (BMJ)
- Distinct symptom pattern emerges for COVID-19 long-haul (Scientific Reports)
- Dr. Griffin's treatment guide (pdf)
- Contribute to Floating Doctors fundraiser at PWB
- Letters read on TWiV 941
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]